RxDoctor Payments DataLook up a doctor →

Alicia Schollmeyer

Family · Shreveport, LANPI 1275800344

Payments from drug & device makers

$14,141in general payments, 2019–2025

Across 491 payments — averaging $28.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$3K
  • Amgen$887
  • AstraZeneca$878
  • Myriad Genetic Laboratories, Inc.$601
  • Johnson & Johnson$596
  • Incyte Corporation$569
  • plus $8K from 54 others

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis72$2,505
Amgen41$887
AstraZeneca(2 entities)29$878
Myriad Genetic Laboratories, Inc.7$601
Johnson & Johnson28$596
Incyte Corporation13$569
Astellas Pharma US Inc19$547
E.r. Squibb & Sons, L.L.C.17$443
Merck25$436
AbbVie19$401
Genentech USA, Inc.20$344
Daiichi Sankyo Inc.15$306
Pharmacyclics LLC, An Abbvie Company14$284
Regeneron Healthcare Solutions, Inc.7$280
Exelixis Inc.4$274
Eisai Inc.16$266
Lilly USA, LLC2$250
Gilead3$231
Sanofi7$215
Bayer6$213
Sun Pharmaceutical Industries Inc.9$212
Sobi, Inc6$212
Jazz Pharmaceuticals Inc.4$189
Ipsen Biopharmaceuticals, Inc4$188
GSK4$171
Bristol Myers Squibb9$169
Servier Pharmaceuticals LLC3$168
Seagen Inc.5$161
Takeda Pharmaceuticals U.S.A., Inc.6$150
Tempus AI, Inc2$147
Coherus Oncology, Inc.9$126
AVEO Pharmaceuticals, Inc.1$125
Blueprint Medicines Corporation1$125
Springworks Therapeutics, Inc.1$125
Pfizer7$116
G1 Therapeutics, Inc.1$100
Sanofi-aventis U.S. LLC1$100
EMD Serono, Inc.4$86
Pharmacosmos Therapeutics Inc.4$69
Pharmaessentia USA Corporation3$66
Taiho Oncology, Inc.2$66
Recordati_rare_diseases_inc.3$66
Dova Pharmaceuticals4$65
Karyopharm Therapeutics Inc.4$63
Stemline Therapeutics Inc.3$53
Aurinia Pharma U.S., Inc.2$52
Rigel Pharmaceuticals, Inc.3$43
Acrotech Biopharma Inc.2$38
ADC Therapeutics America, Inc.2$37
Beigene USA, Inc.2$37
Puma Biotechnology, Inc.3$36
Mirati Therapeutics, Inc.1$32
Progenics Pharmaceuticals, Inc.1$31
Sumitomo Pharma America, Inc.1$23
Genmab U.S., Inc.1$23
Shield Therapeutics Inc1$21
Evoke Pharma, Inc.1$18
CTI Biopharma Corp.1$18
AMAG Pharmaceuticals, Inc.1$16
Kyowa Kirin, Inc.1$16

How this compares

$14,141 in reported general payments places this provider in the 95th percentile of 3,610 family providers in Louisiana.

See all family providers in Louisiana →

Medicare billing

Part B allowed, 2024
$403,141
Medicare patients
234
Services billed
23,388

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other family in Shreveport

See the full list for Louisiana →

Where these figures come from

Is this you, or does something look wrong? →